Skip to search formSkip to main contentSkip to account menu

cabergoline

Known as: cabergoline parkinsons, Cabergolina, (8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide 
A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (3)

Antineoplastic AgentsAntiparkinson AgentsDopamine Agonists
ErgolinesErgot AlkaloidsHyperprolactinemiaHypersensitivity

Narrower (2)

FCE 21336Galastop

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome…
Review
2011
Review
2011
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
The Movement Disorder Society (MDS) Task Force on Evidence‐Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD… 
Review
2011
Review
2011
Place of cabergoline in acromegaly: a meta-analysis.
CONTEXT Cabergoline is widely considered to be poorly effective in acromegaly. OBJECTIVE The aim of this study was to obtain a… 
Highly Cited
2009
Highly Cited
2009
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
BACKGROUND The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated. AIM The aim of… 
Highly Cited
2007
Highly Cited
2007
Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
BACKGROUND Ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson's disease, have been associated… 
Review
2006
Review
2006
A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Highly Cited
2003
Highly Cited
2003
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
BACKGROUND Gender differences in tumor size are supposed to exist in hyperprolactinemia since microadenomas are more commonly… 
Highly Cited
2000
Highly Cited
2000
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a subsequent response to long-term… 
Review
1999
Review
1999
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological… 
Highly Cited
1998
Highly Cited
1998
Cabergoline in the treatment of acromegaly: a study in 64 patients.
Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)